Eisai Co., Ltd. and Merck announced that the China National Medical Products Administration (NMPA) approved the kinase inhibitor Lenvima (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. In China, the application of Lenvima was submitted in October 2017 and was designated for Priority…